Est. 2001·3,000+ placements · six offices · four regions
Concord — source image

Image via AdExchanger

Product Launchcurated sourcedetected 2026-06-23 · confidence 70%

Last updated

Concord: Product Launch

Concord, a France-based platform for agentic media execution, is positioning itself in the emerging market for agentic execution layers in advertising technology. The founder Nathan Venezia notes that agentic execution platforms are harder to come by than agentic measurement tools, suggesting Concord is filling a gap in the market.

Source: AdExchanger

The leadership read

Product momentum tends to widen the sector product and commercial leadership bench strength.

Market context: MitchelLake's Talent Market Index sits at 112.9 (Hot), up 11.4 on the prior month; EMEA hiring signal is running easing (-3.2pts).

Concord: 3 signals in the last 90 days; 0.1% of MitchelLake's Americas signal flow; 3 tracked across 6 days.

Also at Concord

More signals across EMEA

Product Launch · EMEA

Siteimprove

Siteimprove launched a new MCP (Model Context Protocol) Server that integrates accessibility capabilities into AI workflows across Lovable, Anthropic Claude, VS Code, and Figma, enabling automated accessibility in digital experience creation.

Product Launch · EMEA

ST Engineering

ST Engineering secured a US$87.1 million UK defence contract to provide nine variants of 40mm high and low velocity grenades to the military.

Product Launch · EMEA

CSL

CSL's Tavenos product faced a regulatory setback in the European Union, flagged as a potential challenge to the biotechnology major

Product Launch · EMEA

JFrog

JFrog is gaining analyst momentum for AI-focused tools and software supply chain security offerings, with strong traction in managing AI development workflows and securing cloud-native software pipelines.

Product Launch · EMEA

Globant

Globant introduced AI Pods-powered Synthetic Operator for automated live-stream monitoring, targeting mission-critical media workflows with agentic AI tools.

Product Launch · EMEA

MSD

MSD's pembrolizumab received NICE recommendation for locally advanced cervical cancer (LACC), representing first immunotherapy approval in this indication in England

Weekly briefing

Track companies like Concord — with our analysis

Anyone can set an alert for one company. We send a weekly read on the whole peer set — who's moving, and what it means for leadership. Pick what to follow:

Intelligence powered by Autonodal ↗

Share: WhatsApp · X · Email